PUBLICATIONS DES MEMBRES

Biomarkers France contributors. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
2016 - Barlesi F,Mazieres J,Merlio JP,Debieuvre D,Mosser J,Lena H,Ouafik L,Besse B,Rouquette I,Westeel V,Escande F,Monnet I,Lemoine A,Veillon R,Blons H,Audigier-Valette C,Bringuier PP,Lamy R,Beau-Faller M,Pujol JL,Sabourin JC,Penault-Llorca F,Denis MG,Lantuejoul S,Morin F,Tran Q,Missy P,Langlais A,Milleron B,Cadranel J,Soria JC,Zalcman G Lancet n°2 - pp 1415-1426
Biomarkers of residual disease after neoadjuvant therapy for breast cancer
2016 - Penault-Llorca F,Radosevic-Robin N Nat Rev Clin Oncol n°9 - pp 1
Characterization by microarray and meiotic segregation study of a der(10)t(10;18) in a patient with infertility and normal phenotype
2016 - Kemeny S,Brugnon F,Eymard-Pierre E,Goumy C,Janny L,Tchirkov A,Francannet C,Vago P,Pebrel-Richard C Asian J Androl n°Mar 15 - pp 1
Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer
2016 - Bozec A,Ebran N,Radosevic-Robin N,Sudaka A,Monteverde M,Toussan N,Etienne-Grimaldi MC,Nigro CL,Merlano M,Penault-Llorca F,Milano G Laryngoscope n°126(4) - pp 156-163
Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue
2016 - Vilasco M,Communal L,Hugon-Rodin J,Penault-Llorca F,Mourra N,Wu Z,Forgez P,Gompel A Breast Cancer Res Treat n°156(2) - pp 401-402
Pregnancy outcomes in prenatally diagnosed 47,XXX and 47,XYY syndromes: a 30-year French, retrospective, multicentre study
2016 - Gruchy N, Blondeel E, Le Meur N, Joly-Hélas G, Chambon P, Till M, Herbaux M, Vigouroux-Castera A, Coussement A, Lespinasse J, Amblard FJimenez M,Lebel-Roy C,Carré-Pigeon F,Flori E,Mugneret F,Jaillard S,Yardin C,Harbuz R,Collonge-Rame MA,Vago P,Valduga M,Leporrier N,Vialard F Prenet Diagn n°Mar 28 - pp 1
Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer
2016 - Michiels S,Pugliano L,Marguet S,Grun D,Barinoff J,Cameron D, Cobleigh M, Di Leo A, Johnston S, Gasparini G, Kaufman B, Marty M, Nekjudova V, Paluch-Shimon S,Penault-Llorca F,Slamon D,Vogel C,Vonminckwitz G,Buyse M,Piccart M Ann Oncol n°8 - pp 1
Strategy for molecular testing in pulmonary carcinoma
2016 - Penault-Llorca F,Tixier L,Perrot L,Cayre A Ann Pathol n°36(1) - pp 73-79
The JMJD3 Histone Demethylase and the EZH2 Histone Methyltransferase in Prostate Cancer
2016 - Daures M,Ngollo M,Judes G,Rifai K,Kemeny JL,Penault-Llorca F,Bignon YJ,Guy L,Bernard-Gallon D OMICS n°20 (2) - pp 123-125
The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study
2016 - Mahammedi H,Planchat E,Pouget M,Durando X,Curé H,Guy L,Vanpraagh I,Savareux L,Atger M,Bayet-Robert M,Gadea E,Abrial C,Thivat E,Chollet P,Eymard JC Oncology n°90(2) - pp 69-78
The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer
2016 - Ladoire S,Enot D,Senovilla L,Ghiringhelli F,Poirier-Colame V,Chaba K,Semeraro M,Chaix M,Penault-Llorca F,Arnould L,Poillot ML,Arveux P,Delaloge S,Andre F,Zitvogel L,Kroemer G Autophagy n°12(5) - pp 864-875
The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer
2016 - Ladoire S,Enot D,Senovilla L,Ghiringhelli F,Poirier-Colame V,Chaba K,Semeraro M,Chaix M,Penault-Llorca F,Arnould L,Poillot ML,Arveux P,Delaloge S,Andre F,Zitvogel L,Kroemer G Autophagy n°12(5) - pp 864-875
Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer
2016 - Dequeker EM,Keppens C Egele C,Delen S,Lamy A,Lemoine A,Sabourin JC,Andrieu C,Ligtenberg M,Fetique D,Tops B,Descarpentries C,Blons H,Denoux Y,Aube C,Penault-Llorca F,Hofman P,Leroy K,Lemarechal C,Doucet L,Duranton-Tanneur V,Pedeutour F,Soubeyran I,Cote JF,Emile JF,Vignaud JM,Monhoven N,Haddad V,Laurent-Puig P,Vankrieken H,Nowak F,Lonchamp E,Bellocq JP,Rouleau E J Mol Diagn n°18(2) - pp 205-214
Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study
2016 - Bertucci F,Fekih M,Autret A,Petit T,Dalenc F,Levy C,Romieu G,Bonneterre J,Ferrero JM,Kerbrat P, Soulie P,Mouret-Reynier MA,Bachelot T,Lerebours F,Eymard JC,Deblock M,Lortholary A,Hardy-Bessard AC,Barthelemy P,Bonnefoi H,Charafe-Jauffret E,Bidard FC,Viens P,Lemonnier J,Pierga JY Lancet Oncol n°Mar 28 - pp 1
Epigenetic Modifications with DZNep, NaBu and SAHA in Luminal and Mesenchymal-like Breast Cancer Subtype Cells
2016 - Dagdemir A,Judes G,Lebert A,Echegut M,Karsli-Ceppioglu S,Rifaï K,Daures M,Ngollo M,Dubois L,Penault-Llorca F, Bignon YJ,Bernard-Gallon D Cancer genomics and proteomics n°1 - pp 1
Genesis: a French national resource to study the missing heritability of breast cancer
2016 - Sinilnikova OM,Dondon MG,Eon-Marchais S,Damiola F.,Barjhoux L,Marcou M,Verny-Pierre C, Sornin V,Toulemonde L,Beauvallet J,Legal D,Mebirouk N,Belotti M,Caron O,Gauthier-Villars M, Coupier I,Buecher B,Lortholary A,Dugast C,Gesta P,Fricker JP,Noguès C,Faivre L,Luporsi E, Berthet P,Delnatte C,Bonadona V,Maugard CM,Pujol P,Lasset C,Longy M,Bignon YJ,Claude Adenis C BMC cancer n°Jan 12 - pp 1
High-throughput « Omics » technologies: New tools for the study of triple-negative breast cancer
2016 - Judes G,Rifai K,Daures M,Dubois L,Bignon YJ,Penault-Llorca F,Bernard-Gallon D Cancer Letter n°7 - pp 1
Multicentric neoadjuvant pilot phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer
2016 - Nabholtz JM, Chalabi N, Radosevic-Robin N, Dauplat MM, Mouret-Reynier MA, Van Praagh I, Servent V, Jacquin JP, Benmammar KE, Kullab S, Bahadoor MR, Kwiatkowski F, Cayre A, Abrial C, Durando X, Bignon YJ, Chollet P, Penault-Llorca F Int J Cancer n°138(9) - pp 2274-2280
The new combination docetaxel, prednisone and curcumin in patients with castration-resistant prostate cancer: a pilot phase II study
2016 - Mahammedi H,Planchat E,Pouget M,Durando X,Cure H,Guy L,Vanpraagh I,Savareux L,Atger M,Bayet-Robert M,Abrial C,Thicat E,Chollet P,Eymard JC Oncology n°Jan - pp 1